Cargando…
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
Despite major advances in targeted melanoma therapies, drug resistance limits their efficacy. Long noncoding RNAs (lncRNAs) are transcriptome elements that do not encode proteins but are important regulatory molecules. LncRNAs have been implicated in cancer development and response to different ther...
Autores principales: | Sanlorenzo, Martina, Vujic, Igor, Esteve-Puig, Rosaura, Lai, Kevin, Vujic, Marin, Lin, Kevin, Posch, Christian, Dimon, Michelle, Moy, Adrian, Zekhtser, Mitchell, Johnston, Katia, Gho, Deborah, Ho, Wilson, Gajjala, Abhinay, Oses Prieto, Juan, Burlingame, Alma, Daud, Adil, Rappersberger, Klemens, Ortiz-Urda, Susana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053443/ https://www.ncbi.nlm.nih.gov/pubmed/30026510 http://dx.doi.org/10.1038/s41598-018-27643-3 |
Ejemplares similares
-
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
por: Vujic, Igor, et al.
Publicado: (2016) -
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
por: Vujic, Igor, et al.
Publicado: (2014) -
Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015) -
Mutant NRAS(Q61) shares signaling similarities across various cancer types – potential implications for future therapies
por: Vujic, Igor, et al.
Publicado: (2014) -
MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas
por: Posch, Christian, et al.
Publicado: (2018)